In addition, MASLD patients showed a substantial increase in serum FABP4 levels compared with those without liver disease (33, 34), and this upregulation persisted in MASLD-HCC patients (34). This evidence concerns the gene FABP4 and metabolic dysfunction-associated steatotic liver disease.